Table 1 Correlation between H3S10 phosphorylation levels of tumor, PRM, and DRM with clinicopathological variables
Total (n = 101) | H3S10 phosphorylation level of tumor | p value | H3S10 phosphorylation level of PRM | p value | H3S10 phosphorylation level of DRM | p value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Low (%), n = 42 | Inter. (%), n = 44 | High (%), n = 15 | Low (%), n = 76 | Inter. (%), n = 19 | High (%), n = 6 | Low (%), n = 57 | Inter. (%), n = 40 | High (%), n = 4 | ||||
Age (years) | ||||||||||||
 ≤50 | 15 (35.7) | 18 (40.9) | 6 (40.0) | 0.879‡ | 31 (40.8) | 6 (31.6) | 2 (33.3) | 0.734‡ | 21 (36.8) | 16 (40.0) | 2 (50.0) | 0.849‡ |
 >50 | 27 (64.3) | 26 (59.1) | 9 (60.0) | 45 (59.2) | 13 (68.4) | 4 (66.7) | 36 (63.2) | 24 (60.0) | 2 (50.0) | |||
Sex | ||||||||||||
 Male | 29 (69.0) | 32 (72.7) | 9 (60.0) | 0.652‡ | 53 (69.7) | 11 (57.9) | 6 (100.0) | 0.148‡ | 40 (70.2) | 26 (65.0) | 4 (100.0) | 0.343‡ |
 Female | 13 (31.0) | 12 (27.7) | 6 (40.0) | 23 (30.3) | 8 (42.1) | 0 (0.0) | 17 (29.8) | 14 (35.0) | 0 (0.0) | |||
WHO classification | ||||||||||||
 WD | 2 (4.8) | 0 (0.0) | 0 (0.0) | 0.0001 ‡ | 2 (2.6) | 0 (0.0) | 0 (0.0) | 0.008 ‡ | 2 (3.5) | 0 (0.0) | 0 (0.0) | 0.0001 ‡ |
 MD | 22 (52.4) | 3 (6.8) | 0 (0.0) | 24 (31.6) | 1 (5.3) | 0 (0.0) | 23 (40.4) | 2 (5.0) | 0 (0.0 | |||
 PD | 16 (38.1) | 40 (40.9) | 7 (46.7) | 44 (57.9) | 16 (84.2) | 3 (50.0) | 29 (50.9) | 33 (82.5) | 1 (25.0) | |||
 SRC | 2 (4.8) | 1 (2.3) | 8 (53.3) | 6 (7.9) | 2 (10.5) | 3 (50.0) | 3 (5.3) | 5 (12.5) | 3 (75.0) | |||
T stage | ||||||||||||
 T1 | 9 (21.4) | 4 (9.1) | 1 (6.7) | 0.005 †| 13 (17.1) | 1 (5.3) | 0 (0.0) | 0.001 †| 11 (19.3) | 3 (7.5) | 0 (0.0) | 0.003 †|
 T2 | 11 (26.2) | 10 (22.7) | 3 (20.0) | 22 (28.9) | 2 (10.5) | 0 (0.0) | 14 (24.6) | 10 (25.0) | 0 (0.0 | |||
 T3 | 16 (38.1) | 20 (45.5) | 2 (13.3) | 26 (34.2) | 10 (52.6) | 2 (33.3) | 23 (40.4) | 15 (37.5) | 0 (0.0) | |||
 T4 | 6 (14.3) | 10 (22.7) | 9 (60.0) | 15 (19.7) | 6 (31.6) | 4 (66.7) | 9 (15.8) | 12 (30.0) | 4 (0.0) | |||
Lymph node metastasis | ||||||||||||
 Absent | 20 (47.6) | 27 (61.4) | 10 (66.7) | 0.136†| 42 (55.3) | 10 (52.6) | 5 (83.3) | 0.385†| 30 (52.6) | 24 (60.0) | 3 (75.0) | 0.311†|
 Present | 22 (52.4) | 17 (38.6) | 5 (33.3) | 34 (44.7) | 9 (47.4) | 1 (16.7) | 27 (47.4) | 16 (40.0) | 1 (25.0) | |||
pTNM stage | ||||||||||||
 I | 14 (33.3) | 7 (15.9) | 1 (6.7) | 0.016 †| 20 (26.3) | 2 (10.5) | 0 (0.0) | 0.015 †| 17 (29.8) | 5 (12.5) | 0 (0.0) | 0.037 †|
 II | 15 (35.7) | 22 (50.0) | 6 (40.0) | 33 (43.4) | 8 (42.1) | 2 (33.3) | 22 (38.6) | 20 (50.0) | 1 (25.0) | |||
 III | 13 (31.0) | 14 (31.8) | 7 (46.7) | 22 (28.9) | 8 (42.1) | 4 (66.7) | 17 (29.8) | 14 (35.0) | 3 (75.0) | |||
 IV | 0 (0.0) | 1 (2.3) | 1 (6.7) | 1 (1.3) | 1 (5.3) | 0 (0.0) | 1 (1.8) | 1 (2.5) | 0 (0.0) | |||
Recurrence | ||||||||||||
 Absent | 32 (76.2) | 28 (63.6) | 7 (46.7) | 0.034 †| 54 (71.1) | 8 (42.1) | 5 (83.3) | 0.351†| 43 (75.4) | 23 (57.5) | 1 (25.0) | 0.012 †|
 Present | 10 (23.8) | 16 (36.4) | 8 (53.3) | 22 (28.9) | 11 (57.9) | 1 (16.7) | 14 (24.6) | 17 (42.5) | 3 (75.0) | |||
Treatment modality | ||||||||||||
 Surgery | 24 (57.1) | 21 (47.7) | 12 (80.0) | 0.093‡ | 43 (56.6) | 11 (57.9) | 3 (50.0) | 0.943‡ | 28 (49.1) | 26 (65.0) | 3 (75.0) | 0.087‡ |
 NACT + Surgery | 18 (42.9) | 23 (52.3) | 3 (20.0) | 33 (43.4) | 8 (42.1) | 3 (50.0) | 29 (50.9) | 14 (35.0) | 1 (25.0) | |||